Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)

Publication Date

2025

Content Type

article

PubMed ID:

41129765

Additional Authors:

Additional Authors and Institutional Affiliations

This document is currently not available here.

Share

COinS